TINFE

TINFE is a cloud-based software solution that solves a widespread accuracy problem in laboratory fluorescence spectroscopy assays: the "Inner Filter Effect" (IFE). This optical distortion corrupts biological and pharmaceutical data, typically causing errors of 5–25% and resulting in costly retesting, lab throughput delays, and regulatory risks. TINFE automatically corrects this distortion without any new hardware, expensive upgrades, or disruptive changes to existing lab workflows.

Why It Matters Now:

·       Regulatory: Today, labs like contract research organisations (CROs) face intense pressure from their sponsors and from tightening regulatory requirements (such as EU Clinical Trial Regulation 536/2014 in Europe and Good Laboratory Practice (GLP) standards globally), demanding greater accuracy, transparency, and efficiency.

·       Financial: Traditional methods to manage IFE – such as repeated dilutions, additional control assays, or significant hardware upgrades – cost a typical lab approximately €20,000 per month in lost productivity, materials, and labour. This hidden problem risks scientific credibility, slows project timelines, and directly impacts CRO profitability.

TINFE directly addresses this challenge, enabling labs to consistently produce reliable data faster and more economically. The simple-to-adopt & simple-to-use SaaS integrates into standard lab processes and delivers validated results within seconds.

Validation & Unfair Advantages:

1.              TINFE has been successfully validated in early pilots with 3 respected academic labs

2.              TINFE has secured non-dilutive grants and awards, reinforcing technical credibility and early market validation

3.              Intellectual property is currently being secured, with key patent applications pending, creating significant defensibility and barriers to competitor entry

4.              TINFE was developed by two leading PhD chemistry professors, with decades of experience in the IFE field

Funding Ask & Use of Funds:

TINFE is raising a pre-seed round of €700,000. A sum of €300k has been offered by Vesna Capital (a specialist European deep tech fund), potentially as our anchor seed backer – they have already underwritten our proof-of-concept grant and secured IP transfer from Zagreb University.

The funding will directly support market entry, sales and marketing expansion, regulatory compliance groundwork (ISO 13485 and GLP alignment), IP protection, and ongoing product development (including planned hardware partnerships and OEM integrations).

Long-Term Vision:

Initially targeting mid-sized European CROs, TINFE’s vision extends into broader global pharmaceutical and biotechnology markets.

Future growth strategies (Y3–4+) include expanding into additional Ideal Customer Profile lab categories (e.g. pharma, biotech, academic labs, clinical diagnostics) and partnering with global distributors and equipment manufacturers (OEMs) to build a comprehensive, defensible ecosystem around fluorescence assay accuracy.

Quantified Value Proposition

1.              Hard savings: TINFE typically saves mid-sized labs around €20k per month in consumables, labour, and avoided reruns – a 3–6× ROI at list price

2.              Commercial edge: CROs can now quote/boast “IFE‑certified accuracy” in bids with results that are reliable and accurate

3.              Regulatory reassurance: A fully traceable correction log helps labs meet EU‑CTR and GLP audit requirements without adding extra paperwork or slowing operations

4.              Rapid deployment: Install and live in <1 hour via a secure web licence and lightweight local connector. Minimal disruption to SOPs, no new hardware for plate readers (if purchased in the last ten years)

Total Addressable Market (TAM), Serviceable Market (SAM), and Obtainable Market (SOM)

TINFE is entering a high value, under-served category within the global lab testing and analysis market. Our current focus (fluorescence correction in plate reader assays) solves a persistent and costly artefact (the Inner Filter Effect) that limits assay reliability across a broad spectrum of lab types.

“Realistic Today” Market Opportunity

TAM: €1.13 billion | SAM: €422 million | SOM: €51 million

TINFE’s current Total Addressable Market includes fluorescence-heavy labs across:

·       Pharma/Industrial QC labs

·       Clinical Diagnostics labs

·       Food & Beverage testing labs

·       Environmental testing labs

·       Biotech/Pharma/Academic R&D

·       Contract Research Organisations (CROs)Based on global lab counts, average instrument installations, and 2 users per machine (technician and scientist/manager), we estimate 150,000 fluorescence plate readers in global use today with 300,000 users.